Cargando…
Part 1: The Wider Considerations in Translating Heart Failure Guidelines
Congestive Heart Failure (CHF) is an emerging epidemic. Within one generation, the medical community has learned much of CHF syndromes. It has two distinct mechanisms, systolic and diastolic abnormalities, to account for the common CHF presentation. It is complex as it challenges the available healt...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950449/ https://www.ncbi.nlm.nih.gov/pubmed/33423650 http://dx.doi.org/10.2174/1573403X16666210108104945 |
_version_ | 1784675143430176768 |
---|---|
author | Iyngkaran, Pupalan Wilson, Andrew Wong, James Prior, David Kaye, David Hare, David L. Bergin, Peter Jelinek, Michael |
author_facet | Iyngkaran, Pupalan Wilson, Andrew Wong, James Prior, David Kaye, David Hare, David L. Bergin, Peter Jelinek, Michael |
author_sort | Iyngkaran, Pupalan |
collection | PubMed |
description | Congestive Heart Failure (CHF) is an emerging epidemic. Within one generation, the medical community has learned much of CHF syndromes. It has two distinct mechanisms, systolic and diastolic abnormalities, to account for the common CHF presentation. It is complex as it challenges the available health care services, resource, and funding models in providing an equitable service across the health continuum. Despite the improvement in many cardiovascular diseases, some CHF outcomes like readmissions and costs have increased. The reinvigoration of evidence-based medicine, the development of health services models of care, and standardisation of disease processes with taxonomies have also occurred within the same time span. These processes, however, need to be linked with health policy as presented in white papers. In this paper, we explore achieving optimal CHF guideline-recommended outcomes as the science approaches real- world translation. |
format | Online Article Text |
id | pubmed-8950449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-89504492022-10-22 Part 1: The Wider Considerations in Translating Heart Failure Guidelines Iyngkaran, Pupalan Wilson, Andrew Wong, James Prior, David Kaye, David Hare, David L. Bergin, Peter Jelinek, Michael Curr Cardiol Rev Article Congestive Heart Failure (CHF) is an emerging epidemic. Within one generation, the medical community has learned much of CHF syndromes. It has two distinct mechanisms, systolic and diastolic abnormalities, to account for the common CHF presentation. It is complex as it challenges the available health care services, resource, and funding models in providing an equitable service across the health continuum. Despite the improvement in many cardiovascular diseases, some CHF outcomes like readmissions and costs have increased. The reinvigoration of evidence-based medicine, the development of health services models of care, and standardisation of disease processes with taxonomies have also occurred within the same time span. These processes, however, need to be linked with health policy as presented in white papers. In this paper, we explore achieving optimal CHF guideline-recommended outcomes as the science approaches real- world translation. Bentham Science Publishers 2021-10-22 2021-10-22 /pmc/articles/PMC8950449/ /pubmed/33423650 http://dx.doi.org/10.2174/1573403X16666210108104945 Text en © 2021 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Iyngkaran, Pupalan Wilson, Andrew Wong, James Prior, David Kaye, David Hare, David L. Bergin, Peter Jelinek, Michael Part 1: The Wider Considerations in Translating Heart Failure Guidelines |
title | Part 1: The Wider Considerations in Translating Heart Failure Guidelines |
title_full | Part 1: The Wider Considerations in Translating Heart Failure Guidelines |
title_fullStr | Part 1: The Wider Considerations in Translating Heart Failure Guidelines |
title_full_unstemmed | Part 1: The Wider Considerations in Translating Heart Failure Guidelines |
title_short | Part 1: The Wider Considerations in Translating Heart Failure Guidelines |
title_sort | part 1: the wider considerations in translating heart failure guidelines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950449/ https://www.ncbi.nlm.nih.gov/pubmed/33423650 http://dx.doi.org/10.2174/1573403X16666210108104945 |
work_keys_str_mv | AT iyngkaranpupalan part1thewiderconsiderationsintranslatingheartfailureguidelines AT wilsonandrew part1thewiderconsiderationsintranslatingheartfailureguidelines AT wongjames part1thewiderconsiderationsintranslatingheartfailureguidelines AT priordavid part1thewiderconsiderationsintranslatingheartfailureguidelines AT kayedavid part1thewiderconsiderationsintranslatingheartfailureguidelines AT haredavidl part1thewiderconsiderationsintranslatingheartfailureguidelines AT berginpeter part1thewiderconsiderationsintranslatingheartfailureguidelines AT jelinekmichael part1thewiderconsiderationsintranslatingheartfailureguidelines |